Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A critical variation in the provision of prenatal care to women with GDM is the need to keep patients engaged with their care between visits by tracking glucose levels using finger sticks and making dietary and other lifestyle modifications to keep these levels at or close to normal. Multiple studies have demonstrated that the use of mobile devices can improve medical outcomes. In order to keep patients engaged between appointments and improve self-care/lifestyle, we will study the use of a glucose monitoring system with nutrition therapy called GlucoseMama(GM). GM is a mobile app on the iOS system that individuals with GDM will use to tract blood sugars and number of carbs consumed. In addition, it will give the user positive feedback and rewards for using the system. This model of group care with mobile phone monitoring and reminders for women with GDM has not been previously studied. A randomized control trial is purposed to determine if this approach improves patient care. The investigators hypothesize that group prenatal care along with inter-session mobile therapy will increase dietary compliance and therefore reduce the number of individuals requiring pharmacologic therapy and improve neonatal outcomes during pregnancy. Group prenatal care (GPC) will provide a community foundation to improve learning and increase the motivation of patients to learn and change. This motivation will be further strengthened by the use of the GlucoseMama monitoring system which will provide each patient with glucose tracking and individualized nutritional support.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group and Glucose Mama | Experimental | Enrolled subjects with have GlucoseMama application and group care. |
|
| Group and No Glucose Mama | Placebo Comparator | Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application. |
|
| Traditional and glucoseMama | Experimental | Enrolled subjects will have traditional care and glucoseMama |
|
| Traditional and no GlucoseMama | No Intervention | enrolled subjects will not have access to group care or GlucoseMama. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GlucoseMama application with blood sugar monitoring and carb monitoring. | Other | We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals. |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in the number of neonates born large for gestational age. | 2 years | |
| Increased number of individuals who are screened in the postpartum period for type 2 diabetes. | 2 years | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Maryland, Baltimore | Baltimore | Maryland | 21201 | United States |
Not provided
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Group prenatal care for GDM. | Other | group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes. |
|
| Reduction in the number of infants with neonatal hypoglycemia. |
| 2 years |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |